TOC
Home

Rheumatic diseases in focus.
Rheumatic diseases in focus. Shaping health.
German Rheumatology Research Center, a Leibniz Institute

The German Rheumatology Research Center (DRFZ)

German Rheumatology Research Center – Research for Better Therapies in Rheumatology

The DRFZ is conducting research into the causes of rheumatic diseases in order to develop innovative and personalized therapies. Using state-of-the-art technologies such as artificial intelligence and biomarker analysis, we are working on more precise diagnoses and more effective therapies.

Our aim is to improve the quality of life of patients in the long term, close gaps in care and open up new avenues for treatment of rheumatic diseases – by directly transferring research into practice.

Focus on immune cells: advanced technologies at the DRFZ

The DRFZ is revolutionizing immune cell research with innovative technologies. These make it possible to observe, identify and specifically isolate immune cells in their natural tissue environment. After isolation, the cells are comprehensively analyzed in in-depth molecular and functional studies. This creates a new understanding of the complex interactions in the immune system.

Imaging technologies play a central role in biological research by enabling the visualization of cellular and subcellular structures at the highest resolution. Through advanced microscopy techniques, such as confocal and fluorescence microscopy, researchers can observe dynamic processes in living cells and analyze their interactions in real time. These precise visualizations are crucial for deepening the understanding of diseases and identifying new therapeutic targets.

read more…

Information for Patients and interested parties

Research and Rheumatology

Research is a continuous and lengthy process. Developments in the field of rheumatology and immunology have been driven forward with great commitment for many decades and have already achieved significant progress. Although we cannot offer you any direct treatments at the DRFZ, we are working hard to make rheumatism curable. Your well-being is important to us and we are committed to developing innovative solutions for the future.

Figures from the core documentation

54 %

of Lupus patients are treated without cortisone.

67 %

of patients with systemic sclerosis describe their health status as moderate to poor.

55 %

of patients with rheumatoid arthritis are treated with methotrexate.